FDA Drug Regulation & Scheduling Brief

Headline

DEA places cipepofol in Schedule IV via interim final rule effective upon publication

Executive Summary

The DEA issued an interim final rule on August 27, 2026, placing cipepofol (Cypsedo) in Schedule IV of the Controlled Substances Act following FDA approval on May 29, 2026. The rule takes effect immediately, imposing controlled-substance handling, storage, recordkeeping, and dispensing obligations on all registrants who prescribe, dispense, or distribute the drug.

Bottom Line

The interim final rule places cipepofol under Schedule IV controlled-substance requirements as of August 27, 2026. Every DEA registrant in the chain, from manufacturer through dispensing facility, carries immediate obligations for storage security, inventory recordkeeping, and prescription compliance. Facilities that stock or administer cipepofol without updated protocols or correct DEA registration schedules are out of compliance as of the rule's publication date.

Key Regulatory Signals

• Immediate Schedule IV Obligations Apply: Any DEA registrant who handles cipepofol, including hospitals, ambulatory surgical centers, and pharmacies, must now comply with Schedule IV controlled-substance requirements for storage, recordkeeping, inventory, and dispensing. These obligations attach at the rule's effective date, not at a future implementation date.
• Manufacturers and Distributors Must Register or Amend: Entities that manufacture or distribute cipepofol must hold a DEA Schedule IV registration or amend an existing registration before handling the substance. Operating without the correct registration schedule is a federal violation.
• Prescribing Restrictions Now Govern Clinical Use: Cipepofol prescriptions are now subject to Schedule IV federal prescribing limits, including restrictions on refills and mandatory prescription recordkeeping. Anesthesiologists and proceduralists who administer the drug in surgical settings must ensure their institutional protocols reflect these requirements.
• Interim Final Rule Posture Allows Comment but Takes Immediate Effect: The DEA issued this as an interim final rule under the Improving Regulatory Transparency for New Medical Therapies Act, meaning the scheduling is legally operative now. Registrants cannot defer compliance pending a final rule.

Regulatory Delta

- The Improving Regulatory Transparency for New Medical Therapies Act authorizes DEA to bypass the standard proposed-rule comment period for FDA-approved drugs. This scheduling is therefore immediately binding, not prospective.

- Cipepofol shares propofol's drug class as a sedative-hypnotic anesthetic, but carries federal Schedule IV status that propofol does not. Registrants handling cipepofol face a compliance layer with no direct analogue in their existing propofol workflows.

- FDA approval on May 29, 2026 triggered the HHS scheduling recommendation that preceded this DEA action, following the standard post-approval controlled-substance pathway under the Controlled Substances Act.

Materiality Classification

HIGH — Interim final rule with immediate effect under the Improving Regulatory Transparency for New Medical Therapies Act; all DEA registrants handling cipepofol must comply with Schedule IV controlled-substance requirements as of August 27, 2026, with no grace period before the final rule.

Intelligence Outlook

Monitor the Federal Register and DEA Diversion Control Division for the final rule following the interim comment period, and for any DEA guidance addressing registrant transition procedures for cipepofol.